Legend Biotech reported a 36% increase in CARVYKTI sales to $710 million in Q3 2026, driven by expanded global access and updated NCCN guidelines favoring CAR-T therapy for multiple myeloma. Five-year data from the CARTITUDE-2 trial showed half of patients remained alive and progression-free after a single CARVYKTI infusion, supporting its curative potential. The company also received FDA clearance for a new dual-targeting CAR-T therapy, LB2501, and appointed Ingrid Zhang as CEO. Legend Biotech posted a net income of $51.7 million for the quarter, a significant turnaround from a loss the previous year, signaling strong financial health and growth prospects.
Legend Biotech's Q3 2026 results and recent highlights provide context for readers following biotech developments. For readers following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: Out of 150 priced health-sector US stocks tradable on Pluang, 85 rose and 56 fell today. Notable movers include TVTX (Travere Therapeutics Inc. Common Stock) at USD 50.50 with a 1-day change of -2.19% and a typical hold time on Pluang of 8 days; BNGO (BioNano Genomics Inc) at USD 1.18, up 1.72%, with a typical hold time of 53 days and Pluang order activity showing 100% sell; and RVTY (Revvity Inc) at USD 163.18, up 1.53%, with a typical hold time of 14 days and 100% sell order activity on Pluang.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
